Beneficial Effect of Adjuvant Dabrafenib Plus Trametinib on Recurrence-Free Survival in Patients With Resected BRAFV600-Mutant Stage III Melanoma Seems to be Short-Lived

摘要

In their recent article in , Hauschild et al reported relapse-free survival (RFS) results after extended follow-up in a randomized trial with adjuvant dabrafenib (D) plus trametinib (T) in patients with resected -mutant stage III melanoma. They reported an overall hazard ratio estimate of 0.47 in favor of D plus T. Kaplan-Meier plots suggest that there is a sustained treatment effect because the 4-year RFS rates were 54% in the D plus T arm and 38% in the placebo arm.